Reed Smith partner Kevin Madagan and associate Julia Lake will return for a second year to help lead a four-hour “Ad Promo Primer” at the Drug Information Association (DIA)’s “Advertising and Promotion Regulatory Affairs Conference,” which will be held virtually May 18-20, 2020. In addition, Kevin, a member of this year’s planning committee, will be leading a DIA discussion about pricing disclosures and communications.
California Governor Gavin Newsom’s Executive Order N-43-20 (the Order), which went into effect on April 3, 2020, relaxes various telehealth reporting requirements, penalties, and enforcements otherwise imposed under state laws, including those associated with unauthorized access and disclosure of personal information through telehealth mediums. The Order acknowledged that telehealth services may help reduce the spread of COVID-19, and strict compliance with certain state telehealth requirements would otherwise “prevent, hinder, or delay appropriate actions to prevent and mitigate the effects of the COVID-19 pandemic.” This Order affects certain health care facilities, health care providers, health care administrators, clinics, home health agencies, and hospice providers, generally in instances where non-compliance occurs during the “good faith provision of telehealth services.” Although the Order should provide comfort to health entities engaged in telehealth services, this Order remains in effect only through the state of emergency. Moreover health entities should continue to remain steadfast in protecting personal information from unauthorized access or use during COVID-19 and beyond. For a more in-depth explanation of the Order, please visit our Technology Law Dispatch blog
Pharmaceutical manufacturers, as well as other companies affected by or included in changes to pharmaceutical supply chains, are invited to join us tomorrow, April 7, for a complimentary webinar focused on current issues facing the global pharmaceutical supply chain.
- The steps that companies need to take now given the potential for international arbitration claims to arise from challenges such as export restrictions in India and decreased manufacturing of active pharmaceutical ingredients in China and elsewhere.
- Clause drafting issues.
- The consequences of choosing common law over civil law as the governing law of the contract.
- How to select arbitrators for pharmaceutical supply chain disputes.
- How companies should address indemnification obligations and insurance matters.
To register for the webinar, please click here.
This program is presumptively approved for 1.0 general CLE credit in California, Illinois, New Jersey, Pennsylvania, Texas and West Virginia. For lawyers licensed in New York, this course is eligible for 1.0 credit under New York’s Approved Jurisdiction Policy. Please allow four weeks after the program to receive a certificate of attendance.
The United States recently passed the “Coronavirus Aid, Relief, and Economic Security Act” (CARES Act), sweeping legislation that could impact pharmaceutical and medical device companies with U.S. operations or significant U.S. sales.
A team of Reed Smith life sciences and health care lawyers, including Scot T. Hasselman, Robert J. Hill, Carol Colborn Loepere, Kevin M. Madagan, Paul W. Pitts, James F. Segroves, Nicole J. Aiken-Shaban, Julia Krebs-Markrich, Debra A. McCurdy, John D. Kendzior, Jamie Knauer, Arielle R. Lusardi, Rahul Narula, Sonia T. Nguyen, Sung W. Park, and Ryan M. Pate has authored a white paper that provides in-depth analysis of major policy and funding provisions in the Act. In addition, Reed Smith has published a CARES Act Overview, which covers all portions of the Act, and is compiling additional thought leadership at our CARES Act Resource Center.
The Telephone Consumer Protection Act (the TCPA) restricts telemarketing and the use of automated telephone equipment for phone calls, faxes, and text messages. In an effort to ease restrictions in light of the COVID-19 outbreak, the Federal Communications Commission (FCC) has issued guidance clarifying that informational calls that are directly related to the imminent health or safety risk arising out of the COVID-19 outbreak and made by certain types of callers are exempt from the TCPA requirements under the “emergency purposes exception.”
The FCC’s guidance, issued as a Declaratory Ruling on March 20, 2020 (the “Ruling”), explains that the FCC has determined that the COVID-19 outbreak constitutes “an imminent health risk to the public” under the “emergency purposes” exception described above. The Ruling further provides criteria for determining whether a call relating to the COVID-19 pandemic qualifies for the exception:
- The caller must be: (1) calling from a hospital, (2) a health care provider, (3) a state or local health official, or other government official, or (4) a person acting on behalf of such an organization and on its express direction; and
- The content of the call must be solely informational, made necessary as a result of the COVID-19 outbreak, and directly related to the imminent health or safety risk arising out of the COVID-19 outbreak.
With businesses of all types – and especially health care providers – dealing with unprecedented changes to their business models, the TCPA and other privacy laws include exceptions for certain disclosures and communications. The FCC’s confirmation that the COVID-19 outbreak qualifies for such an exception is not surprising but should provide comfort to health care providers who are trying to communicate with patients about necessary appointment changes, office closings, and safety precautions. Health care providers should still be thoughtful in their communications to ensure that they remain purely informational and should watch for additional guidance from the FCC when the pandemic wanes and such communications are no longer necessary.
Read more about this guidance on our Technology Law Dispatch blog.
Medical device manufacturers, who may already be seeing the effects of lessened demand stemming from a slow-down of elective procedures outside of the United States, should be aware of recent guidance the U.S. Centers for Medicare and Medicaid Services (CMS) issued to health care providers urging limitations on elective surgeries and nonessential procedures. As an example, nonurgent spine and orthopedic implants (such as hip and knee replacements and elective spine surgeries) in healthy patients were included among the types of procedures CMS recommends that providers consider postponing.
If they serve health care professionals (HCPs) in EU member states, manufacturers that provide personal protective equipment (PPE) or medical devices used by HCPs caring for known or suspected COVID-19 patients should familiarize themselves with a recent European Commission recommendation. This recommendation is designed to accelerate the time to market for these products, provided that safety is not compromised.
For more information on the recommendation and how it contrasts with the typical steps to commercialize medical devices under the EU Medical Device Regulation (MDR) and PPE under the EU PPE regulation, please see my recent client alert, “Accelerated access to EU market for COVID-19 medical devices and personal protective equipment.”
Global life sciences companies have been carefully watching the European effort to launch a Unified Patent Court (UPC). As we discussed in a previous post, the UPC would have a profound effect on how life sciences companies set about their patent strategies – from filing through exploitation to enforcement.
Efforts to implement the UPC, however, have ended up facing considerable challenges. The Hungarian Constitutional Court found the Hungarian act ratifying the Agreement on a Unified Patent Court (UPCA) unconstitutional. The UK government eventually stated the country would not participate in the new patent litigation system. And, significantly, the Constitutional Court in Germany, the country in which two-thirds of all patent infringement cases in Europe are brought, started examining the constitutionality of the national law ratifying UPCA following a filed complaint by a single patent practitioner.
On Friday, March 20, the German Constitutional Court confirmed that the law was void. For more on this important development and its implications, please see our client alert, “A never-ending story ends? German law ratifying UPCA is void.”
Certain health care providers, health information technology (IT) developers, and health plans could see the way they share patient information transformed following the release of two new final rules issued by the U.S. Department of Health and Human Services. The rules address interoperability and information blocking. Reed Smith partner Nancy Bonifant Halstead and senior associate Vicki Tankle provide an overview on key provisions of these rules in their post on our Health Industry Washington Watch blog.
As corporations continue to grapple with economic issues surrounding COVID-19, global life sciences companies must start to determine how laws in each of the jurisdictions in which they operate will impact their contractual responsibilities and opportunities for remedies in their business relationships.
Life sciences companies with operations in France must recognize that their COVID-19 response will likely need to be different than their responses to previous crises, and not only because French law has significantly changed since 2008.
Our recent client alert, “France – Coronavirus (COVID-19) and economic downturn: What impacts on the continuation of business relationships?” outlines a practical scaled approach to these issues.